Reported Earnings • Mar 21
Full year 2025 earnings released: ₩1,837 loss per share (vs ₩3,541 loss in FY 2024) Full year 2025 results: ₩1,837 loss per share (improved from ₩3,541 loss in FY 2024). Net loss: ₩24.0b (loss narrowed 27% from FY 2024). Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 34% per year, which means it is significantly lagging earnings. Tillkännagivande • Mar 06
CJ Bioscience, Inc., Annual General Meeting, Mar 26, 2026 CJ Bioscience, Inc., Annual General Meeting, Mar 26, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 14, sejong-daero, jung-gu, seoul South Korea Tillkännagivande • Feb 26
CJ BIO Announces the Publication of Clinical Research Findings on Its Postbiotic Ingredient, BiomeNrich Post SZ075 CJ BIO announced the publication of clinical research findings on its postbiotic ingredient, BiomeNrich POST SZ075, in an international peer-reviewed journal. The study strengthens the scientific foundation of the ingredient and supports its positioning as a science-based inner beauty solution. The global beauty and personal care market is rapidly shifting toward "Beauty from within" approaches that improve skin condition through internal health support. In particular, the gut-skin axis has emerged as a key biological pathway linking gut microbiota to skin health, driving increased research into probiotic and postbiotic-based ingestible skincare solutions. At the same time, consumers increasingly seek objective and measurable evidence addressing visible skin concerns such as UV-induced photoaging, barrier impairment, dryness, roughness, and loss of elasticity. As a result, clinically validated biomarkers and instrumental assessments have become critical in substantiating functional ingredient claims. BiomeNrich Post SZ075 is a postbiotic ingredient within CJ BIO's Condition-Specific biotics solution brand, BiomeN rich. It is a 100% plant-based postbiotic produced by fermenting rice germ using Latilactobacillus sakei, a strain originally isolated from kimchi. The ingredient is positioned to support Sleep & Skin Health, developed based on the gut-skin axis concept for inner beauty and mental wellness applications. The newly published study evaluated the ingredient's mechanisms of action in improving skin health and Influencing skin-related biomarkers. Findings demonstrated significant modulation of key markers associated with barrier integrity, hydration, and wrinkle appearance, including reductions in wrinkle severity and transepidermal water loss (TEWL), alongside increases in skin elasticity and dermal density. Dual-Action Efficacy of BiomeNrich postbiotic for Skin Health: A clinical study (n=111, 12 weeks, 500 mg/day) published in Food Science and Biotechnology (2025) confirms the dual functionality of BiomeNrich Post SZ075 in combating UV-induced wrinkles and enhancing hydration. Skin wrinkle and roughness: Compared to the placebo, the test group showed significant resilience against UV-induced damage: 1,140% improvement in wrinkle parameters around the eyes. 614% increase in skin elasticity. 172% increase in dermal density. Skin hydration and Transepidermal Water Loss: The study also demonstrated improvements in hydration-related and barrier-related parameters: 1,872% decrease in Transepidermal Water loss (TEWL); 497% improvement in skin roughness and 280% reduction in desquamation. 309% increase in skin moisture content. Detailed research data on BiomeNrich™?Post SZ075 can be found in CJ BIO's Nutrition Insight article. Differentiation Through Integrated Evidence: CJ BIO established a multi-layered validation framework for BiomeNrich post SZ075, encompassing in vitro, in vitro, in vitro, and human clinical studies. This stepwise research design enables mechanistic verification alongside measurable clinical outcomes, strengthening scientific credibility. This integrated validation framework enables brand partners to reference both mechanistic insights and clinical findings when developing product concepts. In addition to the published clinical study on skin health, CJ BIO has also conducted research exploring sleep-related benefits of BiomeNrich Post SZ075, supporting its potential relevance across multiple wellness applications. Reported Earnings • Mar 21
Full year 2024 earnings released: ₩3,541 loss per share (vs ₩3,235 loss in FY 2023) Full year 2024 results: ₩3,541 loss per share (further deteriorated from ₩3,235 loss in FY 2023). Net loss: ₩32.8b (loss widened 43% from FY 2023). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Tillkännagivande • Mar 05
CJ Bioscience, Inc., Annual General Meeting, Mar 26, 2025 CJ Bioscience, Inc., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 14, sejong-daero, jung-gu, seoul South Korea Tillkännagivande • Feb 18
Cj Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate Cjrb-201 At 'Ecco2025' CJ Bioscience, Inc. announced that it will present preclinical data on its novel drug candidate CJRB-201 at the European Crohn's and Colitis Organization (ECCO) 2025, set to take place from February 19 to 22 in Berlin, Germany. ECCO is a leading international conference in the field of inflammatory bowel disease (IBD), attracting gastroenterologists, researchers, and major pharmaceutical companies from around the world. CJRB-201 is a microbiome-based drug candidate identified through CJ Bioscience's AI-powered drug discovery platform, Ez-Mx®?, and is being developed for the treatment of inflammatory bowel disease. The company has selected CJRB-201 as the next drug candidate following its oncology lead asset, CJRB-101, and will present its anti-inflammatory effects and mechanism of action at ECCO 2025 supported by immunological analysis and preclinical animal studies. CJRB-201 analyzed 500 metagenomic datasets from both IBD patients and healthy individuals and found that CJRB-201, the bacterial strain of Faecalibacterium, was significantly reduced in IBD patients compared to healthy individuals. Faecalibacterium is a key commensal bacterium in the gut, and its depletion has been closely linked to Crohn's disease and autoimmune disorders, making it a promising therapeutic target. Among 60 Faecalibacterium strains analyzed, CJRB-201 exhibited the strongest ability to induce regulatory T cells (Tregs), which play a critical role in mitigating immune dysregulation. In mouse models, CJRB-201 significantly improved key disease markers, including inhibition of weight loss, reduction in disease activity index, histopathological improvement, suppression of pro-inflammatory cytokine secretion, and improvement of colon length. Notably, CJRB-201 demonstrated comparable efficacy to an antibody-based therapy in a preclinical model while offering additional advantages in safety and oral convenience. The company also announced its plan to initiate its first-in-human study in 2026 based on the promising preclinical results. Furthermore, CJRB-201 is conducting research to maximize the therapeutic potential of CJRB-201 by exploring dietary fibers and mechanisms of action (MoA). The company is utilizing the SHIME (Simulator of the Human Intestinal Microbial Ecosystem) system to identify dietary fibers that promote CJRB-201 colonization in the gut. Additionally, it is collaborating with Professor Junuh's research team at Harvard Medical School to further investigidate CJRB-201's MoA, aiming to overcome the limitations of existing microbiome-based therapeutics and accelerate CJRB-201's development. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 43% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 30% per year over the past 5 years. Shareholders have been substantially diluted in the past year (43% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩4.0b revenue, or US$2.7m). Market cap is less than US$100m (₩125.2b market cap, or US$85.9m). New Risk • Jan 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 43% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 30% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (43% increase in shares outstanding). Revenue is less than US$5m (₩4.0b revenue, or US$2.7m). Market cap is less than US$100m (₩132.2b market cap, or US$89.8m). Tillkännagivande • Dec 19
CJ Bioscience, Inc. announced that it has received KRW 40.00000224 billion in funding from CJ Cheiljedang Corporation On December 17, 2024, CJ Bioscience, Inc. closed the transaction. Tillkännagivande • Dec 11
CJ Bioscience, Inc. announced that it expects to receive KRW 40.00000224 billion in funding from CJ Cheiljedang Corporation CJ Bioscience, Inc. announced a private placement of 3,952,960 common shares at a price of KRW 10,119 for gross proceeds of KRW 40,000,002,240 on December 9, 2024. The transaction includes participation from returning investor, CJ Cheiljedang Corporation. The transaction has been approved by the board of directors of the company. The payment date of the transaction is December 17, 2024. The issuance is subject to 1 year lockup . New Risk • Nov 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 34% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Revenue is less than US$5m (₩4.9b revenue, or US$3.5m). Market cap is less than US$100m (₩103.6b market cap, or US$74.4m). Reported Earnings • Mar 22
Full year 2023 earnings released: ₩3,235 loss per share (vs ₩5,940 loss in FY 2022) Full year 2023 results: ₩3,235 loss per share (improved from ₩5,940 loss in FY 2022). Net loss: ₩22.9b (loss narrowed 34% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 21% per year whereas the company’s share price has fallen by 24% per year. New Risk • Jan 29
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩133.3b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩43b free cash flow). Earnings have declined by 52% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩5.6b revenue, or US$4.2m). Market cap is less than US$100m (₩133.3b market cap, or US$99.9m). New Risk • Nov 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩43b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩43b free cash flow). Earnings have declined by 52% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risk Revenue is less than US$5m (₩5.6b revenue, or US$4.3m). New Risk • Oct 06
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩131.8b (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩42b free cash flow). Earnings have declined by 56% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Revenue is less than US$5m (₩5.1b revenue, or US$3.8m). Market cap is less than US$100m (₩131.8b market cap, or US$97.9m). New Risk • Aug 30
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 55% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩30b free cash flow). Earnings have declined by 59% per year over the past 5 years. Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Revenue is less than US$5m (₩4.6b revenue, or US$3.4m). New Risk • Jul 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩119.6b (US$92.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩30b free cash flow). Earnings have declined by 59% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Revenue is less than US$5m (₩4.6b revenue, or US$3.5m). Market cap is less than US$100m (₩119.6b market cap, or US$92.1m). Reported Earnings • Mar 26
Full year 2022 earnings released: ₩5,940 loss per share (vs ₩4,533 loss in FY 2021) Full year 2022 results: ₩5,940 loss per share (further deteriorated from ₩4,533 loss in FY 2021). Net loss: ₩34.9b (loss widened 81% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings. Tillkännagivande • Jul 23
ChunLab, Inc. announced that it expects to receive KRW 73.24122766 billion in funding from CJ Cheiljedang Corporation ChunLab, Inc. announced a private placement of 1,954,924 common shares at an issue price of KRW 37,465 per share for gross proceeds of KRW 73,241,227,660 on July 21, 2021. The transaction will include participation from CJ Cheiljedang Corporation. The company will issue shares through third party allotment method. The transaction has been approved by the board of directors of the company. The securities issued are subject to restriction period of one year. The payment date is October 29, 2021. Is New 90 Day High Low • Feb 22
New 90-day low: ₩38,700 The company is down 7.0% from its price of ₩41,800 on 24 November 2020. The South Korean market is up 18% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare Services industry, which is down 14% over the same period. Is New 90 Day High Low • Dec 15
New 90-day low: ₩39,600 The company is down 20% from its price of ₩49,650 on 16 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is down 11% over the same period. Tillkännagivande • Sep 04
ChunLab, Inc. announced that it has received KRW 30 billion in funding On September 2, 2020, ChunLab, Inc. (KOSDAQ:A311690) closed the transaction. Tillkännagivande • Sep 01
ChunLab, Inc. announced that it expects to receive KRW 30 billion in funding ChunLab, Inc. (KOSDAQ:A311690) announced a private placement of Series 1 Unregistered Nonguaranteed private convertible bond for gross proceeds of KRW 30,000,000,000 on August 31, 2020. The transaction will include participation from Aion Elpis Hedge Fund for KRW 24,000,000,000 and Kiwoom-Aion Kosdaq Scale-Up Private Equity Fund for KRW 6,000,000,000. The bond carries zero coupon rate and yield to maturity of 2%. The bond will mature on September 2, 2025. The bond will be 100% convertible into 575,882 common shares of the company at price of KRW 52,094. The conversion period is from September 2, 2021 to August 2, 2025. The transaction is expected to close on September 2, 2020. The transaction has been approved by the board of directors of the company. The securities issued are subject to restriction period of one year.